

RISCC



first risk-based
screening for
**cervical
cancer**
in Europe

RISCC is a
multidisciplinary
consortium of key
researchers in Human
papillomavirus (HPV)
and cervical cancer
prevention.

*This project has received funding from the
European Union's Horizon 2020 research and innovation
programme under grant agreement No 847845.*



BACKGROUND:

There is a pressing need to change the current cervical cancer screening in Europe:


HPV vaccinated women are reaching screening age, and their precancer risk differs greatly from unvaccinated women with the same test result.

Improved technologies should be applied on the screening program with limited consequences for management.

In risk-based screening programs, clinical management is provided according to each woman's individual risk of precancer based on her screening history, vaccination status and other risk factors. It prioritizes women at high risk, reduces distress and overtreatment for women at lower risk (by avoiding unnecessary tests) and reduces costs and burden: in Europe, investing 2€ per woman annually can cut the current incidence of cervical cancer in half.

METHODOLOGY:

- Define risk profiles based on screening history, vaccination status and other risk factors such as age.
- Provide screening recommendations for different levels of precancer risk.
- Assess the cost-effectiveness of risk-based cervical cancer screening programs.
- Conduct a pilot risk-based screening program for cervical cancer in Europe.
- Develop and provide open-source IT tools to facilitate clinical management.
- Offer free online training for personnel involved in screening programs.



For more information about the project,
visit our website:

www.riscc-h2020.eu

